Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Medical Devices & Technology (Technology)
2010: *Top 10 hospital technology transfer programs by 2010 license income
*Pioneers: Hospitals & Healthcare
*Pioneers: Biodefense & Pandemic Resilience
*BioSTL_CDM (Center for Defense Medicine)

Precision Virologics

Parents

Develops adenovirus-based vaccines
Dr. David Curiel, MD, PhD, CEO, Precision Virologics, Washington University (2021)
Founded 2016
Obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19.
Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets.
Precision Virologics is a vaccine company developing advanced generation adenoviral vaccines. :Precision’s lead agent is a potency enhanced simian adenovirus-based COVID-19 vaccine delivered via the nasal route.: Precision also has vaccine development programs for influenza, Zika, and chikungunya. :Advanced molecular engineering of adenovirus provides technology platforms to provide key advantages.: Precision’s unique capabilities provide ideal positioning for rapid development of effective vaccines for emerging bioweapon and pandemic threats.